{"protocolSection": {"identificationModule": {"nctId": "NCT02429258", "orgStudyIdInfo": {"id": "D1690L00026"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin", "officialTitle": "Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin"}, "statusModule": {"statusVerifiedDate": "2017-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-05"}, "primaryCompletionDateStruct": {"date": "2015-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-04-08", "studyFirstSubmitQcDate": "2015-04-28", "studyFirstPostDateStruct": {"date": "2015-04-29", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-10-07", "resultsFirstSubmitQcDate": "2017-02-27", "resultsFirstPostDateStruct": {"date": "2017-04-11", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-05-18", "lastUpdatePostDateStruct": {"date": "2017-06-14", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Effect of Dapagliflozin on 24-hour Blood Glucose in Type 2 Diabetes Patients Inadequately Controlled With Either Metformin Or Insulin", "detailedDescription": "Effect of Dapagliflozin on 24-hour Blood Glucose in 92 Type 2 Diabetes Patients Inadequately Controlled With Either Metformin Or Insulin"}, "conditionsModule": {"conditions": ["Type II Diabetes"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 226, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Farxiga with metformin or insulin", "type": "EXPERIMENTAL", "description": "Farxiga with metformin (\\>/=1500mg/day) or insulin (\\>/=30 units/day) and up to 2 OAD medications", "interventionNames": ["Drug: Farxiga", "Drug: Metformin", "Drug: Insulin"]}, {"label": "Placebo with metformin or insulin", "type": "PLACEBO_COMPARATOR", "description": "Placebo with metformin (\\>/=1500mg/day) or insulin (\\>/=30 units/day) and up to 2 OAD medications", "interventionNames": ["Drug: Placebo", "Drug: Metformin", "Drug: Insulin"]}], "interventions": [{"type": "DRUG", "name": "Farxiga", "description": "Farxiga 10mg/day", "armGroupLabels": ["Farxiga with metformin or insulin"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo", "armGroupLabels": ["Placebo with metformin or insulin"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin background therapy \\>/= 1500mg/day", "armGroupLabels": ["Farxiga with metformin or insulin", "Placebo with metformin or insulin"]}, {"type": "DRUG", "name": "Insulin", "description": "Insulin \\>/= 30 units", "armGroupLabels": ["Farxiga with metformin or insulin", "Placebo with metformin or insulin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in 24-hour Mean Weighted Glucose (MWG) From Baseline to End of Treatment (Week 4) Using the Continuous Glucose Monitoring (CGM) System", "timeFrame": "Baseline to Week 4"}], "secondaryOutcomes": [{"measure": "Change in the 24-hour Mean Ampitude of Glucose Excursions (MAGE) From Baseline to Week 4", "timeFrame": "Baseline to Week 4"}, {"measure": "Change in Percentage of CGM Readings Over 24-hours With Plasma Glucose <70 mg/dL From Baseline to Week 4 - ITT Population", "timeFrame": "Baseline to Week 4"}, {"measure": "Change in Percentage of CGM Readings Over 24-hours With Plasma Glucose Between 70 mg/dL and 180 mg/dL From Baseline to Week 4 - ITT Population", "timeFrame": "Baseline to Week 4"}, {"measure": "Change in Percentage of CGM Readings Over 24-hours With Plasma Glucose >180 mg/dL From Baseline to Week 4 - ITT Population", "timeFrame": "Baseline to Week 4"}, {"measure": "Change in Fasting Plasma Glucose (FPG) From Baseline to Week 4", "timeFrame": "Baseline to Week 4"}, {"measure": "Change in 4-hour Mean Weighted Post-prandial Glucose (PPG) (After the Standardized Breakfast Meal) From Baseline to Week 4", "timeFrame": "Baseline to Week 4"}, {"measure": "Change in HbA1c From Baseline to Week 4", "timeFrame": "Baseline to Week 4"}, {"measure": "Change in Fructosamine From Baseline to Week 4", "timeFrame": "Baseline to Week 4"}, {"measure": "Change in 2-hour Mean Weighted PPG (After the Standardized Breakfast Meal) From Baseline to Week 4", "timeFrame": "Baseline to Week 4"}, {"measure": "Change in Static Insulin Secretion Rate (10^-9 Min^-1) From Baseline to Week 4 - ITT Population", "timeFrame": "Baseline to Week 4"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetes mellitus (T2DM)\n* Treated with either stable dose of metformin alone \\> or = to 1500mg/day or stable dose of insulin \\> or = to 30 units/day and up to 2 OAD medications for at least 8 weeks\n* Hemoglobin A1c (HbA1c) 7.5% to 10.5% at screening\n* Body mass index (BMI) \\< or = to 45 kg/m2\n\nExclusion Criteria:\n\n* For patients who enter the study taking a stable dose of metformin, history of taking OAD medications other than metformin during the 8 weeks prior to screening or have been on insulin therapy within 1 year of screening\n* For patients who enter the study taking insulin, history of taking any other therapy outside of the stable insulin and up to 2 OAD medications for 8 weeks prior to screening.\n* Use of sulfonylureas during the 8 weeks prior to screening\n* Prior exposure to dapagliflozin or any sodium-glucose co-transporter 2 (SGLT-2) inhibitor\n* Ingestion of any medication know to affect glucose metabolism for \\>7 consecutive days during the 3 months prior to screening\n* Ingestion of prescription or over the counter weight loss medication during 3 months prior to screening", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Research Site", "city": "Birmingham", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Research Site", "city": "Phoenix", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Research Site", "city": "Huntington Park", "state": "California", "country": "United States", "geoPoint": {"lat": 33.98168, "lon": -118.22507}}, {"facility": "Research Site", "city": "Los Angeles", "state": "California", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Research Site", "city": "Sacramento", "state": "California", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"facility": "Research Site", "city": "San Diego", "state": "California", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Research Site", "city": "West Hills", "state": "California", "country": "United States", "geoPoint": {"lat": 34.19731, "lon": -118.64398}}, {"facility": "Research Site", "city": "Cooper City", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.05731, "lon": -80.27172}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Evanston", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 42.04114, "lon": -87.69006}}, {"facility": "Research Site", "city": "Oxon Hill", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 38.80345, "lon": -76.9897}}, {"facility": "Research Site", "city": "Henderson", "state": "Nebraska", "country": "United States", "geoPoint": {"lat": 40.77973, "lon": -97.81227}}, {"facility": "Research Site", "city": "Brooklyn", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.6501, "lon": -73.94958}}, {"facility": "Research Site", "city": "Rochester", "state": "New York", "country": "United States", "geoPoint": {"lat": 43.15478, "lon": -77.61556}}, {"facility": "Research Site", "city": "Greensboro", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 36.07264, "lon": -79.79198}}, {"facility": "Research Site", "city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Research Site", "city": "Dublin", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 40.09923, "lon": -83.11408}}, {"facility": "Research Site", "city": "Franklin", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.55895, "lon": -84.30411}}, {"facility": "Research Site", "city": "Eugene", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 44.05207, "lon": -123.08675}}, {"facility": "Research Site", "city": "Lansdale", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.2415, "lon": -75.28379}}, {"facility": "Research Site", "city": "Spartanburg", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Research Site", "city": "Bartlett", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 35.20453, "lon": -89.87398}}, {"facility": "Research Site", "city": "Dallas", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Research Site", "city": "Houston", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Research Site", "city": "Hurst", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.82346, "lon": -97.17057}}, {"facility": "Research Site", "city": "Renton", "state": "Washington", "country": "United States", "geoPoint": {"lat": 47.48288, "lon": -122.21707}}]}, "referencesModule": {"references": [{"pmid": "30222367", "type": "DERIVED", "citation": "Henry RR, Strange P, Zhou R, Pettus J, Shi L, Zhuplatov SB, Mansfield T, Klein D, Katz A. Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Technol Ther. 2018 Nov;20(11):715-724. doi: 10.1089/dia.2018.0052. Epub 2018 Sep 14."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "226 subjects signed the informed consent form (ICF), and 132 subjects were screened to randomize a total of 100 subjects.", "groups": [{"id": "FG000", "title": "Dapagliflozin", "description": "Dapagliflozin + Metformin or Insulin"}, {"id": "FG001", "title": "Placebo", "description": "Placebo + Metformin or Insulin"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "50"}, {"groupId": "FG001", "numSubjects": "50"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "48"}, {"groupId": "FG001", "numSubjects": "49"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "100 subjects were included in the safety and ITT population. 99 subjects were included in the evaluable population. 1 subject did not meet the I/E criteria.", "groups": [{"id": "BG000", "title": "Dapagliflozin", "description": "Dapagliflozin + Metformin or Insulin"}, {"id": "BG001", "title": "Placebo", "description": "Placebo + Metformin or Insulin"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "50"}, {"groupId": "BG001", "value": "50"}, {"groupId": "BG002", "value": "100"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56.9", "spread": "7.11"}, {"groupId": "BG001", "value": "56.8", "spread": "9.71"}, {"groupId": "BG002", "value": "56.9", "spread": "8.47"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "49"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "26"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "51"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "25"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "75"}]}]}, {"title": "American Indian and Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}, {"title": "Native Hawaiian or Other Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}, {"title": "More than one race", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "BMI", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "34.3", "spread": "5.92"}, {"groupId": "BG001", "value": "33.2", "spread": "5.59"}, {"groupId": "BG002", "value": "33.8", "spread": "5.75"}]}]}]}, {"title": "Hemoglobin A1c (HbA1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percentage", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.31", "spread": "0.785"}, {"groupId": "BG001", "value": "8.37", "spread": "0.810"}, {"groupId": "BG002", "value": "8.34", "spread": "0.794"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in 24-hour Mean Weighted Glucose (MWG) From Baseline to End of Treatment (Week 4) Using the Continuous Glucose Monitoring (CGM) System", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline to Week 4", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin + Metformin or Insulin"}, {"id": "OG001", "title": "Placebo", "description": "Placebo + Metformin or Insulin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-18.2", "spread": "4.33"}, {"groupId": "OG001", "value": "5.8", "spread": "4.25"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-24.0", "ciPctValue": "95", "ciLowerLimit": "-36.1", "ciUpperLimit": "-12.0", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6.08"}]}, {"type": "SECONDARY", "title": "Change in the 24-hour Mean Ampitude of Glucose Excursions (MAGE) From Baseline to Week 4", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline to Week 4", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin + Metformin or Insulin"}, {"id": "OG001", "title": "Placebo", "description": "Placebo + Metformin or Insulin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.0", "spread": "4.14"}, {"groupId": "OG001", "value": "5.3", "spread": "4.06"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.010", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-15.3", "ciPctValue": "95", "ciLowerLimit": "-26.8", "ciUpperLimit": "-3.8", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "5.80"}]}, {"type": "SECONDARY", "title": "Change in Percentage of CGM Readings Over 24-hours With Plasma Glucose <70 mg/dL From Baseline to Week 4 - ITT Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Change in percentage", "timeFrame": "Baseline to Week 4", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin + Metformin or Insulin"}, {"id": "OG001", "title": "Placebo", "description": "Placebo + Metformin or Insulin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.3", "spread": "0.30"}, {"groupId": "OG001", "value": "-0.6", "spread": "0.29"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.023", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "1.0", "ciPctValue": "95", "ciLowerLimit": "0.1", "ciUpperLimit": "1.8", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.42"}]}, {"type": "SECONDARY", "title": "Change in Percentage of CGM Readings Over 24-hours With Plasma Glucose Between 70 mg/dL and 180 mg/dL From Baseline to Week 4 - ITT Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Change in percentage", "timeFrame": "Baseline to Week 4", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin + Metformin or Insulin"}, {"id": "OG001", "title": "Placebo", "description": "Placebo + Metformin or Insulin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.2", "spread": "2.60"}, {"groupId": "OG001", "value": "-2.8", "spread": "2.55"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "15.0", "ciPctValue": "95", "ciLowerLimit": "7.7", "ciUpperLimit": "22.2", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.65"}]}, {"type": "SECONDARY", "title": "Change in Percentage of CGM Readings Over 24-hours With Plasma Glucose >180 mg/dL From Baseline to Week 4 - ITT Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Change in percentage", "timeFrame": "Baseline to Week 4", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin + Metformin or Insulin"}, {"id": "OG001", "title": "Placebo", "description": "Placebo + Metformin or Insulin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-12.6", "spread": "2.65"}, {"groupId": "OG001", "value": "3.5", "spread": "2.60"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-16.1", "ciPctValue": "95", "ciLowerLimit": "-23.5", "ciUpperLimit": "-8.7", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.72"}]}, {"type": "SECONDARY", "title": "Change in Fasting Plasma Glucose (FPG) From Baseline to Week 4", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline to Week 4", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin + Metformin or Insulin"}, {"id": "OG001", "title": "Placebo", "description": "Placebo + Metformin or Insulin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-26.2", "spread": "5.99"}, {"groupId": "OG001", "value": "3.6", "spread": "5.98"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-29.7", "ciPctValue": "95", "ciLowerLimit": "-46.6", "ciUpperLimit": "-12.9", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "8.47"}]}, {"type": "SECONDARY", "title": "Change in 4-hour Mean Weighted Post-prandial Glucose (PPG) (After the Standardized Breakfast Meal) From Baseline to Week 4", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline to Week 4", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin + Metformin or Insulin"}, {"id": "OG001", "title": "Placebo", "description": "Placebo + Metformin or Insulin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-50.9", "spread": "6.54"}, {"groupId": "OG001", "value": "-10.0", "spread": "6.39"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-40.8", "ciPctValue": "95", "ciLowerLimit": "-59.0", "ciUpperLimit": "-22.7", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "9.14"}]}, {"type": "SECONDARY", "title": "Change in HbA1c From Baseline to Week 4", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "% Alc", "timeFrame": "Baseline to Week 4", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin + Metformin or Insulin"}, {"id": "OG001", "title": "Placebo", "description": "Placebo + Metformin or Insulin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.51", "spread": "0.07"}, {"groupId": "OG001", "value": "-0.28", "spread": "0.07"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.024", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.23", "ciPctValue": "95", "ciLowerLimit": "-0.43", "ciUpperLimit": "-0.03", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.10"}]}, {"type": "SECONDARY", "title": "Change in Fructosamine From Baseline to Week 4", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline to Week 4", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin + Metformin or Insulin"}, {"id": "OG001", "title": "Placebo", "description": "Placebo + Metformin or Insulin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-20.4", "spread": "3.22"}, {"groupId": "OG001", "value": "-9.6", "spread": "3.17"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.019", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-10.8", "ciPctValue": "95", "ciLowerLimit": "-19.9", "ciUpperLimit": "-1.8", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.55"}]}, {"type": "SECONDARY", "title": "Change in 2-hour Mean Weighted PPG (After the Standardized Breakfast Meal) From Baseline to Week 4", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline to Week 4", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin + Metformin or Insulin"}, {"id": "OG001", "title": "Placebo", "description": "Placebo + Metformin or Insulin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-49.5", "spread": "6.61"}, {"groupId": "OG001", "value": "-13.2", "spread": "6.46"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-36.3", "ciPctValue": "95", "ciLowerLimit": "-54.7", "ciUpperLimit": "-17.9", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "9.25"}]}, {"type": "SECONDARY", "title": "Change in Static Insulin Secretion Rate (10^-9 Min^-1) From Baseline to Week 4 - ITT Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "10^-9 min^-1", "timeFrame": "Baseline to Week 4", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin + Metformin or Insulin"}, {"id": "OG001", "title": "Placebo", "description": "Placebo + Metformin or Insulin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.4", "spread": "2.07"}, {"groupId": "OG001", "value": "1.4", "spread": "1.98"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.017", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "7.0", "ciPctValue": "95", "ciLowerLimit": "1.3", "ciUpperLimit": "12.7", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.86"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0.05", "eventGroups": [{"id": "EG000", "title": "Dapagliflozin", "description": "Dapagliflozin + Metformin or Insulin", "seriousNumAffected": 0, "seriousNumAtRisk": 50, "otherNumAffected": 3, "otherNumAtRisk": 50}, {"id": "EG001", "title": "Placebo", "description": "Placebo + Metformin or Insulin", "seriousNumAffected": 0, "seriousNumAtRisk": 50, "otherNumAffected": 3, "otherNumAtRisk": 50}], "otherEvents": [{"term": "Urinary Tract Infection", "organSystem": "Infections and infestations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 50}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 50}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Institution \\& PI agree they will not use or disclose and confidential information to third parties for a period of 10 years from receipt"}, "pointOfContact": {"title": "Sergey Zhuplatov MD, PhD", "organization": "AstraZeneca, PLL", "email": "sergey.zhuplatov@astrazeneca.com", "phone": "215-542-3222"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type II Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000529054", "term": "Dapagliflozin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M348449", "name": "Dapagliflozin", "asFound": "Elimination", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}